Abstract 4691: Rationale for combining PARP inhibitors with topotecan or irinotecan: taking advantage of the alternative DNA repair pathways involving XPF-ERCC1 and PARP-TDP1
Year: 2012
Type: conference-abstract
Source: Cancer Research
Institution: National Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2045987344